Mira pharmaceuticals, inc.MIRA.US Overview
US StockHealthcare
(No presentation for MIRA)
MIRA Overall Performance
MIRA AI Analysis & Strategy
MIRA Recent Performance
0.87%
Mira pharmaceuticals, inc.
0.81%
Avg of Sector
-1.14%
S&P500
MIRA PowerScanner
MIRA Key Information
MIRA Valuation Metrics
MIRA Earnings Table
MIRA Profile
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.